By depleting CD8+ T cells, Park et al. 8 and Stagg et al. 11 also noted the importance of CD8+ T cells in anti-neu mAb therapy in TUBO tumor bearing NeuT transgenic animals resulting in complete tumor regression in 20% of the mice. This evidence concerns the gene CD8A and neoplasm.